A promoter library was developed that is composed of DNA fragments constructed by randomly elongating the cis-acting elements of transcription factors presumably activated in prostate cancer by radiation, and linking to the TATA-box sequence. One promoter with the strongest reactivity to X-ray in the LNCap cells of the library was chosen and improved by the introduction of random mutations. The resultant promoter was designated clone 880-8, showing the highest dose-dependent activity enhancement with X-ray irradiation (X-irradiation). A recombinant retrovirus expressing the luciferase gene under the control of clone 880-8 was infected into LNCap cells that showed 9.12±0.36-fold enhancement of luciferase activity 12 h after X-irradiation at 10 Gy. When the infected cells were inoculated onto nude mice, enhancement of luciferase expression was 4.27 ± 1.36-fold 12 h after X-irradiation at 10 Gy. When LNCap was infected with another recombinant carrying the fcy::fur gene downstream from clone 880-8, fcy::fur expression was enhanced by X-irradiation. It was also shown to increase the dosedependent cell killing ratio with 5-FC as compared with a counterpart without X-irradiation. These results suggest that the method used in this study is effective to construct a promoter responsive to stimulation. Such promoters can be used for stimulation-controlled gene therapies.
INTRODUCTION
For prostate cancer, radiation therapy has been variously applied not only for the eradication but also for the palliative treatment of metastatic lesion in addition to salvage therapy for recurrent disease after radical prostatectomy for local prostate cancer. In low-risk prostate cancer patients, the rate of biological recurrence-free survival after radiation therapy have been comparable to that of radical prostatectomy. 1 It was reported that conventional radiotherapy tended to fail in treating patients with concentrations of prostate-specific antigen over 15. 2 As local recurrence after radiotherapy remains a reality, improvement of treatment strategies is necessary to manage the local and micro-metastatic lesions of prostate cancer. 3, 4 Thus, a more effective radiation therapy has been desired. In addition, as the side effects of radiation therapy are always a concern, any measure to limit these should always be considered.
To address these issues of effectiveness and safety, researchers develop various devices for prostate cancer treatment. For instance, a less invasive 3-dimensional conformal radiotherapy has been designed to treat prostate cancer and was found to be more effective than its predecessors. To more accurately manage the radiation dose, intensity-modulated radiotherapy was also developed. These new methods in radiotherapy are computer-based and use optimized, non-uniform radiation beam intensities for spatially controlled incidence on the patient. 5 Gene therapy is considered one of the new prospective procedures for prostate cancer treatment. Prostate cancer is a particularly suitable malignancy to study, particularly as target for gene therapy, owing to some of its features. 6 The prostate gland is easily accessible by transurethral, transperineal and transrectal approaches for the intratumoral administration of a therapeutic gene. In addition, the prostate gland produces specific gene products, such as prostate secretary protein and prostatic acid phosphate, which may potentially be exploited for vector targeting or gene vaccine immunization.
Since the first clinical study concerning gene therapy for prostate cancer was performed, 7 large numbers of clinical studies concerning gene therapy for prostate cancer have been reported. [8] [9] [10] However, gene therapy does not still become a general procedure for prostate cancer treatment, because of its associated challenges, including low transduction efficiency, low specificity to the target tissue and adverse side effects of the cytotoxicity of a therapeutic gene product.
It has been pointed out that combination of radiation therapy and gene therapy, called 'radio-genetic therapy' , is an attractive prospect, [11] [12] [13] as the combination may potentially overcome these defects of either therapy. It may use a gene whose product is capable of improving the anticancer effects of ionizing radiation, and/or controlling the expression of therapeutic genes by irradiation. The latter could be attained using a promoter whose activity is controlled by ionizing radiation. The cellular response to ionizing radiation induces the transcriptional activation of a number of genes involved in immediate-early responses to mitogenic stimulation or cellular stress. These transcriptional activations are achieved through the binding of transcription factors activated by ionizing radiation to the corresponding cis-acting elements in the promoter. It is reasonable to use such a promoter for constructing a vector system for the combination therapy including egr-1, p21 and others that were successfully used to control transgene expression by ionizing radiation in vitro and in vivo. [14] [15] [16] [17] However, the reactivity of naturally occurring promoters may have some physiological limitations, and this has prompted us to develop artificial X-rayinducible promoters.
In our previous report we indicated that it was possible to construct a radiation-responsive promoter by linking the randomly elongating cis-acting elements to which radiation-activated transcription factors bind with a DNA fragment containing the TATA-box sequence. In addition, it was shown that randomly introducing mutations into a radiation-responsive promoter could enhance its reactivity to radiation. However, it turned out that the response of the promoter to X-ray irradiation (X-irradiation) was cell type-dependent because no activation was observed in some of the cell lines tested. 18 In this study, we constructed a radiation-responsive promoter that functions in prostate cancer cells by using the cis-acting elements of the transcription factors activated in prostate cancer cell lines by radiation stimulation. Then we examined a constructed radiation-responsive promoter for its therapeutic use against a prostate cancer cell line.
RESULTS

Construction of a promoter responsive to radiation in prostate cancer cell lines
Promoters artificially constructed by using DNA fragments containing the cis-acting elements of nuclear factor-kB (NF-kB), NF-Y, activator protein (AP-1) and CArG binding factor-A were found to be responsive to X-irradiation in HeLa cells at a high probability rate. However, the promoter showing the highest reactivity to radiation was not or only weakly responsive in prostate cancer cell lines. 18 As the promoter was chosen out of a promoter library consisting of only 11 different clones, to expand our possibilities of generating a promoter responsive to radiation in prostate cancer cells, we prepared another promoter library consisting of 64 possible promoter fragments constructed by using the cis-acting elements of the same set of transcription factors, applying essentially the same technique, and designated it the 'four ciselement promoter library' . As many cell lines would show similar reactions to radiation, including stress responses, DNA repair and apoptosis, we assumed that a set of transcription factors activated by radiation was similar to some extent even in cell lines derived from different tissue origins. Each of the possible promoter fragments was cloned immediately upstream from the luciferase gene in a plasmid vector. The human prostate cancer cell lines LNCap, DU145 and PC-3 were transfected with each of the plasmids and subsequently exposed to 10 Gy X-ray, and then subjected to dual luciferase assay 6 h after the X-irradiation. Among them, the highest reactivity for LNCap, DU145 and PC-3 was 1.28 ± 0.21-fold, 2.43 ± 0.27-fold and 1.23 ± 0.13-fold, respectively, as compared with that of their non-irradiated counterparts (data not shown). Although these enhancements were statistically significant, we judged that the reactivity was not sufficient for the purpose of radio-genetic therapy.
We considered that the above obtained results may be because of differences in a set of transcription factors activated in response to the same stimulation when cellular origins are different. To construct a better promoter library for prostate cancer cells, we chose five transcription factors of NF-kB, AP-1, Oct-1, p53 and Nrf-2, all of which were reportedly responsive to radiation stimulation in prostate cancer cells. [19] [20] [21] [22] [23] Using synthesized DNA fragments containing the corresponding cis-acting elements in addition to a DNA fragment containing the TATA-box sequence from the human heme oxygenase-I gene promoter, 24 another promoter library was prepared and it was designated the 'prostate cancer promoter library' . Twenty-eight constructed promoters were screened for reactivity to X-irradiation in LNCap, DU145 and PC3 cells. Although 24, 8 and 1 clones of the 'prostate cancer promoter library' showed significant enhancements in the LNCap, DU145 and PC3 cells, respectively, the degree of activation was minimal. Even the best clone showed an only 2.1-fold enhancement, and that was in the LNCap cells (data not shown).
Reactivity of all the promoters to radiation was screened 6 h after X-irradiation. However, we thought that we might have chosen a wrong timing for reactivity evaluation as a responsive promoter's activity may reach to its peak at various time points after stimulation depending on the condition. For instance, the egr-1 gene promoter was reported to reach its peak response after a much longer time period following radiation stimulation; although a direct comparison with our results is difficult because of differences in experimental designs. 25 We thus chose six representative clones (clones 804, 830 and 831 from the 'four cis-element promoter library' , and clones 879, 882 and 885 from the 'prostate cancer promoter library') showing relatively higher responses in the first screening to radiation to observe their enhancements in LNCap cells 72 h after X-irradiation at 10 Gy. Three out of the six promoters (clones 804, 879 and 885) showed significantly higher enhancements than those observed 6 h after irradiation ( Figure 1a ). As the promoters in the 'prostate cancer promoter library' showed higher enhancement of 3.87 ± 0.69-fold than those in the 'four cis-element promoter library' that showed enhancement of 2.27 ± 1.14-fold, we rescreened promoters in the 'prostate cancer promoter library' for their enhancement in LNCap cells 72 h after X-irradiation at 10 Gy. Thirteen clones showed significant enhancements. Among them, clone 880 showed the highest enhancement of 6.67 ± 1.09-fold (Figure 1b) .
We constructed control plasmids of identical structural features except for the promoters. They contained promoters known to be responsive to radiation stimulation, including promoters of the p21 gene, the heme oxygenase-1 gene and the egr-1 gene. Although known to be responsive to radiation stimulation, in addition, these genes contained a cis-acting element used to construct the clone 880 promoter, and no other promoter exceeding the enhancement ratio attained by using the clone 880 promoter when irradiated with X-ray at 10 Gy in LNCap cells (Figures 1a and b) .
To further characterize the clone 880 promoter, we performed a series of experiments to observe the kinetics of luciferase activity in LNCap cells after X-irradiation at 2.5, 5 and 10 Gy. In all the cases, enhancements became obvious at 24 h, reaching their peaks at 48 h after X-irradiation and gradually declining thereafter (Figure 2a) . Figure 2b shows a comparison of their peaks of luciferase activity enhancements at 48 h after various doses of X-irradiation, showing a dose-dependent enhancement with X-ray (Figure 2b ). Improvement in X-ray reactivity of clone 880 through introduction of random mutations by error-prone PCR To improve the reactivity of the clone 880 promoter to X-irradiation, we randomly introduced mutations by error-prone PCR. As we reported previously, it could change the properties of a promoter to various directions. 18 Twenty-eight mutant DNA fragments were generated from clone 880 and cloned in the same luciferase expression vector as the promoter libraries. They were evaluated by dual luciferase assay 48 h after X-irradiation at 10 Gy. The results are shown in Figure 2c . While some of them lost or had decreased reactivity to X-ray, a few fragments showed improvements. Among them, one designated clone 880-8 promoter was the most improved, showing 10.4±2.3-fold enhancement. We failed to further improve the reactivity of the promoter to X-irradiation, although 46 fragments were similarly generated from clone 880-8 and subjected to similar evaluation (data not shown).
Nucleotide sequence analyses of clone 880 and clone 880-8 showed that they were 328 bp long and that each of them contained two copies of the NF-kB-binding site, three copies of the Oct-1-binding site, three copies of the p53-binding site and five copies of the Nrf-2-binding site. Construction of a stably transfected LNCap cell line expressing the luciferase gene under the control of clone 880-8 by using a recombinant retrovirus A gene cassette composed of clone 880-8 and the luciferase gene was inserted in between two long terminal repeats (LTRs) of the retroviral vector plasmid pRetroQ-AcGFP1-N-1. The 5¢-LTR is designed to be inactivated after the recombinant viral genome is integrated into the host genome so that interference to internal promoters in the proviral DNA would be at a minimum. The recombinant viral particles in the supernatant of the transfected packaging cells were added to infect LNCap cells. The resultant cell line was designated LNCap-880-8-luc. Kinetics studies of luciferase expression in LNCap-880-8-luc after X-irradiation at 10 Gy were performed by quantitative real-time PCR and by dual luciferase assay. The luciferase transcripts increased after X-irradiation and reached their peak at 6 h, whereas luciferase activity reached its peak at 12 h after X-irradiation. The luciferase transcripts elevated up to 26.4±5.9-fold at their peak as compared with that of the non-irradiated counterpart. In addition, luciferase enzymatic activity increased up to 9.12 ± 0.36-fold at 12 h (Figure 3a) .
To see if oxidative stress could be involved in the mechanism of clone 880-8 promoter activation by X-irradiation, two antioxidant chemicals including D-mannitol and dimethyl sulphoxide were added to LNCap-880-8-luc cell culture immediately before irradiation. Either of the chemicals suppressed the enhancement of luciferase activity dose dependently. Addition of dimethyl sulphoxide at a final concentration of 350 and 700 mM suppressed its enhancement to 63.8 and 52.7% of that without dimethyl sulphoxide (Figure 3b ). In the case of D-mannitol, addition at 50, 100 and 200 mM attenuated promoter activation to 86.0, 60.4 and 20.9% of that without D-mannitol ( Figure 3c ). These results suggest that oxidative stress is involved, at least in part, with the mechanism of promoter activation by X-irradiation.
We then subcutaneously inoculated LNCap-880-8-luc cells on one side and LNCap-SV40-luc cells on the other side of the flanks of a KSN/Slc nude mouse to see if the promoter is responsive to radiation even in vivo. When tumors were formed, the mice were subjected to X-irradiation at 10 Gy. Changes of luciferase expressions were measured in a tumor formed by LNCap-880-8-luc cells inoculated on one side of the flanks and, on the other side, in a tumor formed by LNCap-SV40-luc cells that were referred to as the control. Twelve hours after irradiation, a significant enhancement of luciferase expression of 4.27±1.36-fold (mean±s.e.m.) was observed. By 24 h after irradiation, it decreased to 3.49 ± 2.42-fold (mean ± s.e.m.) (Figure 3d ).
Responses of clone 880-8 to radiation in various cancer cell lines
A constructed recombinant retrovirus generated with pRet-880-8-luc was infected into 11 different cancer cell lines other than LNCap and the responses of the promoter to radiation were then examined by single luciferase assay 12 and 24 h after X-irradiation. As shown in Figure 3e , although there were differences in the degrees of enhancements or timing of peak activity among the cell lines, 5 out of 11 cell lines responded to 10 Gy X-ray, showing significant enhancement. 
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In vivo luciferase expression was augmented in response to X-irradiation at 10 Gy. After similar-sized tumor tissues of LNCap-880-8-luc cells were formed in both the flanks of five nude mice, they were X-irradiated at 10 Gy. Immediately before X-irradiation, and 12 and 24 h after X-irradiation, photons emitted out of each tumor tissue were recorded for bioluminescence image data and they were calculated for changes in luciferase expressions. The bars represent the s.e.m. (n¼5). Statistically significant differences are indicated by asterisks (*Po0.05). (e) The clone 880-8 promoter responded differently to radiation in the eight different cancer cell lines. Transduced cell lines with a gene cassette composed of clone 880-8 and the luciferase gene were exposed to 10-Gy X-irradiation. Cells were harvested and subjected to luciferase assay 12 and 24 h after radiation. The bars represent the s.d.s (n¼3). Statistically significant differences are indicated by asterisks (*Po0.05, **Po0.01).
It was confirmed that, at their peaks, MCF-7 cells showed about 3.96 ± 0.21-fold, A549 cells about 2.96 ± 0.44-fold, SaOS2 cells about 2.01±0.52-fold, SBC-1 cells about 1.80±0.13-fold and HeLa cells showed about 1.64 ± 0.16-fold enhancements as compared with their counterparts without radiation. These data suggest that there are types of cancers that would similarly respond to radiation, and that the same type of promoter could be applied for their treatment.
Radiation facilitation of in vitro 5-FC cytotoxicity to cells expressing the fcy::fur gene under the control of the clone 880-8 promoter To evaluate the potential of the clone 880-8 promoter for therapeutic use, we constructed another recombinant retrovirus expressing the fcy::fur gene, a fusion gene resulting from fusion between yeast the fcy-1 and fur-1 genes encoding cytosine deaminase and uracil phosphoribosyl-transferase, respectively. 26 The fusion protein is confirmed to carry either enzymatic activity. The former enzyme activity catalyzes 5-fluorocytosine (5-FC) into highly toxic 5-fluorouracil (5-FU) and the latter catalyzes the conversion of uracil and 5-FU into UMP and 5-fluoro-UMP, respectively. These chemical interactions are shown to greatly enhance the sensitivity of cells to 5-FC. 27 Stably transfected LNCap cells with the newly constructed recombinant virus were designated LNCap-880-8-fcy::fur. Enhancement of fcy::fur gene expression in response to radiation was confirmed by quantitative real-time PCR and immunoblot analyses. The transcripts increased and reached their peak 6 h after X-irradiation at 10 Gy and gradually declined thereafter. However, enhanced transcription was sustained thereafter, showing 5.51 ± 0.04-fold enhancement at 36 h (Figure 4a ). Regarding the expression of the fusion protein, the result of the immunoblot analysis showed that, although a small amount of the protein was detected 0 h after X-irradiation at 10 Gy, 6 h later the Fcy::Fur fusion protein increased significantly. It peaked at 12 h and remained increased even at 36 h (Figure 4b ).
LNCap-880-8-luc cells or LNCap-880-8-fcy::fur cells were X-irradiated at 10 Gy, and 12 h thereafter, 1-100 mM 5-FC was added to the culture medium. After overnight incubation, the culture medium was changed with medium without 5-FC and then incubation was further performed for 24 h at 37 1C. The amount of surviving cells after the series of incubations was then evaluated by using a WST-1 cell counting kit (Figure 4c 
DISCUSSION
In this report, we showed that a promoter responsive to radiation in prostate cancer cells was successfully constructed by a method described in our previous study, 18 although a set of cis-acting elements used were somewhat different. Combining a DNA fragment A radiation-responsive artificial promoter A Morii et al constructed by using randomly connected five different cis-acting elements to another DNA fragment containing the TATA-box, we constructed a promoter library. Of the 28 promoters in the library, 13 promoters (46.4%) turned out responsive to radiation stimulation in LNCap cells, and the most responsive promoter to radiation, clone 880, was identified and selected for further investigation. Randomly introducing mutations into clone 880 yielded clone 880-8 with improved response to X-irradiation, confirming again the validity of our method in augmenting a certain property of a promoter. However, we could not improve clone 880-8, suggesting that the method has its limitation. The best promoter constructed in this report turned out to be reactive to radiation even under in vivo conditions. In addition, with X-irradiation, it could be used for controlling therapeutic gene expression and augmenting cell cytotoxicity when combined with the fcy::fur gene in the presence of 5-FC in vitro. All these results suggest that a promoter constructed by the method described in the present study, including clone 880-8, can be of potential use in radio-genetic therapy.
To construct a radiation-responsive promoter that functions in prostate cancer cells, we constructed a promoter library composed of 62 potential promoter clones, by using the cis-acting elements of four transcription factors, NF-kB, AP-1, NF-Y and CArG binding factor-A, in addition to one constructed by using the cis-acting elements of five transcription factors, NF-kB, Oct-1, AP-1, Nrf-2 and p53RE. Although the former was found to contain promoters efficiently responsive to radiation in HeLa cells, they did not function effectively in prostate cancer cell lines. By contrast, the clone 880-8 promoter constructed in this study did not show enhancement in HeLa cells in response to radiation as much as that observed in LNCap cells (data not shown). The results confirmed the cell type specificity of the promoters constructed by this method.
Previously constructed promoters reached a peak in their activity at 9 h after radiation stimulation in HeLa cells. On the other hand, the clone 880 promoter constructed in this study was found to reach its peak 48 h after radiation in LNCap cells. There are numbers of transcription factors that are activated in response to stimulation, with varying time periods in reaching peaks after stimulation. In addition, activation of corresponding transcription factors might be an indirect result of radiation stimulation. Moreover, when promoter activity was observed in cells infected with a recombinant virus containing clone 880-8, the time to reach its enhancement peak was lesser than that observed in transient transfection experiments, although the activity of the peak was not changed so much. The reason for this is unclear, but a possible explanation would be that the integrated promoter functioned in a different context so that the activity was possibly affected by adjacent structures and epigenetic conditions.
The construction method for a promoter library described in this report is relatively simple. In addition, a constructed promoter library tends to contain many promoters responsive to radiation stimulation and thus, it would not be a very difficult task to obtain a useful promoter out of such a library by screening (Figure 1c) . 18 Therefore, it should not be impractical to construct promoters for individual cancer treatments. In addition, one promoter could be used for the treatment of multiple types of cancer as it was shown that clone 880-8 was activated by radiation in five cell lines out of 11 different cell lines tested (Figure 2e ). This suggests that a limited number of promoters could cover a wide range of different cancer types.
In in vivo experiment, promoter activity was enhanced significantly in response to radiation stimulation. However, the enhancement ratios were lowered as compared with those observed in in vitro experiments.
They might be because of differences in irradiation efficiencies or detection systems for luciferase expression. It might also be because of modification of transgene activation in the in vivo environment. For instance, mouse blood that supplies cells with nutrition and oxygen contains many different kinds of bioactive factors. One such factor could partially activate clone 880-8. It may raise the basal activity of the promoter in vivo, thus lowering its enhancement ratio. We are currently analyzing the mechanism to solve the problem.
Although the clone 880-8 promoter could potentially be useful for radio-genetic therapy, it still poses challenges that should be solved. First, the clone 880-8 promoter shows relatively high basal activity (activity without enhancement). In our cytotoxicity experiment, with 100 mM 5-FC in the medium, cell killing of LNCap-880-8-fcy::fur cells was obvious even without X-irradiation. In a similar experiment, identically treated LNCap-880-8-luc cells did not show cell killing in the presence of 5-FC at 100 mM, suggesting that clone 880-8 was active to some extent even without X-irradiation. If the promoter is applied as radio-genetic therapy, the basal activity could cause side effects by affecting untargeted tissues as expression of this cytotoxic therapeutic gene cannot be restricted within the radiation area. We are devising a procedure for controlling basal activity by using target sequences of microRNAs expressed in LNCap cells. Second, radiation doses to sufficiently enhance promoter activity were relatively high. For example, radiation cancer therapy rarely uses irradiation up to 10 Gy except in certain instances, including prostate cancer therapy and brachytherapy, where high doses of radiation are sometimes applied. The promoter could be used in combination with such a procedure for clinical application. Especially in patients receiving radiation as radical therapy for prostate cancer by which local recurrence and distant metastasis are frequent occurrences. This combination strategy may improve the clinical outcomes of the patients. In addition, it may prevent an adverse side effect of radiation by reducing the total radiation dose through the effect of the transgene. Finally, the constructed promoter did not show clear reactivity to X-irradiation in the other prostate cancer cells, PC-3 and DU145 cells. As these are hormone-refractory prostate cancer cells, some of the molecular mechanisms might be different from those of LNCap cells that are not hormone-refractory. The constructed promoters were again confirmed to be cell type-specific as we had observed previously. We think that this challenge is not a big difficulty to overcome because we can construct a promoter for each target tumor effectively by applying an appropriate set of cis-acting elements. In the near future, we should make more effective means for constructing promoters with the aim of pursuing the possibility for clinical application.
MATERIALS AND METHODS
Cells and bacteria
The human cancer cell lines, LNCap (prostate), DU145 (prostate), PC-3 (prostate); A549 (lung), SBC1 (lung); T24 (bladder), HTB1 (bladder); HeLa (cervix of uterus), CaSki (cervix of uterus); MCF7 (breast), HMS-1-8 (breast); and SaOS2 (bone) were purchased from the Health Science Research Source Bank (Tokyo, Japan) or the American Type Culture Collection (Manassas, VA, USA). All cells were grown and maintained in RPMI-1640 medium supplemented with 10% fetal calf serum and appropriate antibiotics at 37 1C in a humidified atmosphere containing 5% CO 2 .
The DH5a strain of Escherichia coli (Nippon Gene Co. Ltd, Toyama, Japan) was used for the DNA manipulation experiments. The E. coli cells were grown in LB medium at 37 1C. All medium compositions were purchased from BD Diagnostics (Sparks, MD, USA). The DNA manipulation experiments using E. coli were performed according to the methods described by Sambrook and Russell. 28 A radiation-responsive artificial promoter A Morii et al
Constructions of promoters and vectors
Construction of the promoter probe plasmid vector, pGL3-DU-TATA, has been described elsewhere. 18 For promoter construction, double-stranded synthetic DNA fragments coding for one of four kinds of cis-acting elements, binding sites for NF-kB, AP-1, CArG binding factor-A and NF-Y, and a double-stranded synthetic DNA fragment containing a HindIII recognition site and a KpnI recognition site were used. After these oligomer pairs had been annealed in an annealing buffer, the fragments were treated with T4 polynucleotide kinase at 37 1C for 2 h. These phosphorylated, double-stranded fragments were equally mixed and a 1/100 amount of the HindIII and KpnI fragments was also added for fragment elongation after a series of treatments to construct DNA fragments. After digestion of the resultant DNA fragments with HindIII and KpnI, they were cloned into the HindIII and KpnI sites of pGL3-DU-TATA to construct 62 plasmid vectors (the four cis-element promoter library). Then, pairs (positive and negative strands) of cis-acting element sequences for NF-kB (5-gggactttcc-3¢), AP-1 (5¢-tgactca-3¢), Oct-1 (5¢-atgcaaat-3¢), p53 (5¢-gaacatgtc taagcatgctg-3¢) and Nrf-2 (5¢-tgctgagtca-3¢) were used to construct 28 potential promoters (the prostate cancer promoter library) by essentially the same method. Each of the constructed plasmids of both the libraries were designated pGL3-(clone number)-DU.
Error-prone PCR and cloning of mutated promoter fragments
Random mutations were introduced into a promoter clone by error-prone PCR. 29 pGL3-880-DU (10 ng) with 10 pmol each of 5¢-gctagcccgggctcgagatctgc-3¢ and 5¢-tatgtttttggcgtcttccatgg-3¢ was added to 100 ml of reaction mixture (10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.5 mM MnCl 2 , 0.2 mM dNTP) containing 5 U of Taq polymerase (Takara Bio Inc., Ohtsu, Japan). Amplification was performed with a PCR Express thermal cycler (Hybaid, Heidelberg, Germany) using the following cycling conditions: one cycle at 94 1C for 3 min; 40 cycles of 1 min at 94 1C, 1 min at 62 1C and 3 min at 70 1C; and one cycle at 72 1C for 5 min. The resulting PCR fragments were crude concentrated and digested with BglII and NcoI, and then were cloned into pGL3-DU. 18 
Transient transfection and X-irradiation
The constructed plasmid vectors were transfected by using the Effecten reagent (Qiagen K.K., Tokyo, Japan) according to the manufacturer's instructions. A 60-mm cell culture dish was seeded with 1.5Â10 6 cells and incubated at 37 1C overnight. The cells were washed once with pre-warmed RPMI-1640 and an Effecten complex containing 1.0 or 2.0 mg of a plasmid vector with a constructed promoter and 10 ng phRL-TK (Promega Corp., Madison, WI, USA) was added to each dish. The cells were harvested after incubation at 37 1C for 6 h, and a 35-mm cell culture dish was seeded with 2.0Â10 5 of the harvested cells and incubated at 37 1C overnight. The medium in the 35-mm dish was replaced by 2 ml of pre-warmed RPMI-1640 and then subjected to X-irradiation. Each dish with cells was placed on the turning table in the chamber of an X-ray generator (MBR-1520-3; Hitachi Medical Technology Corp., Tokyo, Japan) for 5-to 15-Gy irradiation at 5 Gy min À1 .
Dual luciferase assay
At various time points after X-irradiation, the medium was removed and 400 ml of passive lysis buffer from the Dual Luciferase Assay kit (Promega Corp.) was added to lyse the cells by shaking for 15 min at an ambient temperature on a platform shaker. A 10-ml volume of the cell lysate supernatant was mixed with 50 ml of the luciferase assay reagent II of the kit to measure the luminescence generated by firefly luciferase, and immediately thereafter 50 ml of the Stop & Glow reagent of the kit were added to the mixture to measure the luminescence generated by the Renilla luciferase expressed from phRL-TK. Each of the promoter's activities was expressed as relative luminescence units, where the value of luminescence by the firefly luciferase was divided by that of the Renilla luciferase expressed in the same lysate. Enhancement of luciferase expression by X-irradiation was expressed as fold activity, where the relative luminescence unit value of a sample with X-irradiation was divided by that of an identically treated sample without X-irradiation.
Single luciferase assay corrected with protein concentration
Between samples exposed to X-ray and samples not exposed, the proportions of Renilla luciferase expression from transiently transfected phRL-TK to firefly luciferase expression from a stably transfected recombinant virus could be different since, as cells proliferate, the firefly luciferase gene increases whereas the Renilla luciferase gene does not. Thus, it is probably better to use protein concentration in a sample of cell lysate as a reference for evaluating enhancement of luciferase expression rather than by dual luciferase assay using the Renilla luciferase gene. At various time points after radiation, the medium was removed and 400 ml of passive lysis buffer from the Dual Luciferase Assay kit (Promega Corp.) were added to lyse the cells by shaking for 15 min at an ambient temperature on a platform shaker. A 10-ml volume of the cell lysate supernatant was mixed with 50 ml of the luciferase assay reagent II of the kit to measure the luminescence generated by the firefly luciferase. Total protein concentration was assayed by the Bradford method by using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The luciferase expression value in a sample was corrected by the protein concentration of the sample.
Recombinant retrovirus production and infection
A retrovirus generation vector, pRetroQ-AcGFP1-N-1, was purchased from Takara Bio Inc. The luciferase gene was obtained by PCR by using pGL3-control (Promega Corp.) as template and the primer pairs 5¢-cgcgggcccaccatggaagacgc caaaaa-3¢ (containing an SmaI site as a tag) and 5¢-cctgaattctatcttatcatgtctgctcg-3¢ (containing an EcoRI site as a tag). After digestion with EcoRI and SmaI, the amplified fragment (the luciferase gene) was purified and ligated into the EcoRI and SmaI sites of pRetroQ-AcGFP1-N-1, constructing a new plasmid pRetroQluc by replacing the GFP gene with the luciferase gene. The clone 880-8 promoter was amplified by PCR by using pGL3-880-8-DU as template and the primer pairs 5¢-ggagctcttacgcgtgctac-3¢ (containing a BglIII site as a tag) and 5¢-tcttccagcggatagaatgg-3¢ (containing an NcoI site as a tag). After digestion with BglII and NcoI, the PCR product was purified and inserted into the BglIII and NcoI sites of pRetroQ-luc, creating a new plasmid, pRet-880-8-luc. A DNA fragment containing the SV40 promoter was also amplified by PCR by using pGL3-Control as template and the primer pairs 5¢-cgcagatctcatctcaattagtcagcaac-3¢ (containing a BglIII site as a tag) and 5¢-gcgggatcctttgcaaaagcctaggcctc-3¢ (containing an NcoI site as a tag). After digestion with BglIII and NcoI, the PCR product was purified and inserted into the BglIII and NcoI site of pRetroQ-luc, creating a new plasmid, pRet-SV40-luc, that was used as a control vector.
To construct recombinants expressing a suicide gene, the fcy::fur fusion gene encoding cytosine deaminase and uracil phosphoribosyl-transferase, a DNA fragment containing the fcy::fur fusion gene with the flag tag sequence (N-AspTyr-Lys-Asp-Asp-Asp-Asp-Lys-C) was obtained by PCR by using the plasmid pORF5-Fcy::Fur (InvivoGen, San Diego, CA, USA) as the PCR template and the primer pairs 5¢-ggctctagattatttagtagtatctgtccc-3¢ (an XbaI recognition site and a flag tag-coding region in addition to a stop codon was attached to the 5¢-terminus) and 5¢-gagacagaggagaccatggtcac-3¢ (an NcoI recognition site was included). After digestion with XbaI and NcoI, the PCR product (an fcy::fur fusion gene fragment) was purified. The fragment was inserted into the XbaI and NcoI sites of pRet-880-8-luc to construct a new plasmid, pRet-880-8-fcy::fur, by replacing the fusion protein gene with the luciferase gene, and another plasmid expressing the fcy::fur fusion gene under the control of the SV40 promoter for a control recombinant virus was constructed similarly by replacing the PCR-amplified fusion gene fragment with the luciferase gene of pRet-SV40-luc to create a new plasmid, pRet-SV40-fcy::fur.
One million AmphoPack293 cells (Takara Bio Inc.) were seeded onto a 60-mm collagen-coated cell culture dish and the following day they were transfected by using the CalPhos Mammalian Transfection kit (Takara Bio Inc.) with 10 mg of pRet-880-8-luc. The virus-containing conditioned medium was collected 48 h after transfection and passed through a 0.45-mm filter to remove debris. Polybrene (Sigma-Aldrich Inc., St Louis, MO, USA) was added to the filtered medium at a final concentration of 7.0 mg ml À1 . This prepared solution was used as a virus source to infect 1Â10 6 LNCap cells. The infected cells were concentrated by puromycin treatment at 0.5 mg ml À1 to which the infected cells were resistant, to establish a stably transfected cell line, LNCap-880-8-luc. A control cell line, LNCap-SV40-luc, was similarly constructed by using pRet-SV40-luc and served as a control cell line. For the other cell lines used for the recombinant virus infection performed in this study, the procedure was identical except for the puromycin concentrations used to concentrate the infectants, which were as follows: 0.5 mg ml À1 for SaOS2; 1.0 mg ml À1 for DU145, SBC1, MCF7, CaSki and T24; and 2.0 mg ml À1 for PC-3, HTB1, A549, HMC-1-8 and HeLa.
Similar recombinant retroviruses were constructed and were used to infect LNCap cells to establish stably transfected cell lines expressing the fcy::fur fusion gene under the control of the clone 880-8 and the SV40 promoters, LNCap-880-8-fcy::fur from pRet-880-8-fcy::fur and LNCap-SV40-fcy::fur cells from pRet-SV40-fcy::fur, respectively.
Quantitative real-time PCR
For evaluation of mRNA expression, quantitative real-time PCR was performed. Total RNA was obtained from adherent tissue culture cells by using the RNeasy Mini kit (QIAGEN K.K.), with treatment with DNase-I according to the manufacturer's instructions. cDNAs were synthesized by using the extracted RNA as template, by using the PrimeScript RT reagent kit (Takara Bio Inc.), according to the manufacturer's instructions. Gene expression analysis was performed by using the Mx3000P QPCR System (Agilent Technologies Inc., Santa Clara, CA, USA), by using the synthesized cDNA. Quantitative PCR measurement by real-time monitoring of SYBR Green integration into the synthesized DNA was performed during a process of shuttle PCR using the following cycling conditions: incubation at 95 1C for 10 s, and then 40 thermal cycles for reactions at 95 1C for 10 s and at 60 1C for 40 s, followed by reactions at 55 1C for 30 s and 95 1C for 30 s using SYBR Premix Ex Taq II (Takara Bio Inc.). After the shuttle PCR, the dissociation temperature of the synthesized DNA fragment was also determined by monitoring the release of SYBR Green from the denatured DNA for confirmation of the integrity of the synthesized DNA fragment. The primer used for the PCR reaction was selected by exploratory experiment from candidate primers designed by Primer3 (v.0.4.0) (http:// frodo.wi.mit.edu/primer3/). We used three primer pairs: 5¢-ccagggatttcagtcg-3¢ and 5¢-aatctcacgcaggcag-3¢ to detect luciferase expression; 5¢-ttgatgagagaccccaggac-3¢ and 5¢-tccacaatctgcttctgcac-3¢ to detect fcy::fur expression; and 5¢-gagt caacggatttggtcgt-3¢ and 5¢-ttgattttggagggatctcg-3¢ to detect glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Relative standard curves representing several 10-fold dilutions of cDNA from a representative sample were used for linear regression analysis for other samples. In this study, the luciferase gene, the fcy::fur gene and a housekeeping gene (GAPDH) were analyzed.
Western blot analysis
At various time points after X-irradiation, cells were harvested and lysed in radioimmunoprecipitation buffer containing a protease inhibitor cocktail. Cell lysate samples containing 30 mg of protein from LNCap-880-8-fcy::fur cells or LNCap-SV40-fcy::fur cells were subjected to sodium dodecyl sulphate-PAGE. The fractionated proteins transferred onto a nitrocellulose film were analyzed using the ANTI-FLAG M2 monoclonal antibody as the primary antibody (Sigma-Aldrich Inc.) and a goat anti-mouse IgG antibody conjugated to horseradish peroxidase as the secondary antibody (Millipore, Billerica, MA, USA). Protein expression was visualized by using ECL Western Blotting Detection Reagents (GE Healthcare UK Ltd, Chalfont St Giles, UK) and image was captured by using the LAS-4000 luminescence imaging analyzer (Fujifilm Corporation, Tokyo, Japan).
Animal studies
All the plans for our experiments using mouse were judged appropriately and permitted for implementation by the Animal Experiment Committee of University of Toyama. LNCap-880-8-luc cells and LNCap-SV40-luc cells were harvested with trypsin and resuspended in phosphate-buffered saline at a concentration of 4Â10 6 cell ml À1 . The cell suspension was mixed with an equal volume of Matrigel basement membrane matrix (BD Diagnostics). Male KSN/ Slc nude mice at age 5 weeks (Sankyo Lab Service, Toyama, Japan) were subcutaneously administered a total of 2.0Â10 6 (500 ml) of these cells-LNCap-880-8-luc into the right flank and LNCap-SV40-luc into the left, respectively. After about 6 weeks, mice bearing tumors of similar size were chosen for an irradiation experiment. All the mice were anesthetized with Nembutal at 500 mg/g body weight. They were then administered luciferin EF (Promega Corp.) intraperitoneally at 100 mg/g body weight. These mice were subjected to analysis using a bioluminescence detecting system (AEQUORIA-2D/c8600; Hamamatsu Photonics K.K., Hamamatsu, Japan) 5 min after substrate administration. Images of luciferase expression were captured with integration time for 60 s using the Wasabi application software (version 1.5; Hamamatsu Photonics K.K.). After that, the tumor tissues of the mice were exposed to X-irradiation at 10 Gy. They were maintained in a cage with free access to food and water for 12 h after the X-ray exposure. The mice were again administered the same amount of luciferin EF after being anesthetized with Nembutal and subjected to analysis using the bioluminescence detecting system to capture images again. Using the Wasabi application software, the captured images were processed for quantifying photons given off out of the tumor tissues. All the mice were brought back to their cages. Twenty-four hours after irradiation, luciferase expressions were evaluated by counting photons with the bioluminescence detecting system given off out of the tumor tissues of the luciferin EF-administered mice. As the SV40 promoter had been confirmed to not have enhanced in response to X-irradiation in the tumor of LNCap cells on nude mouse in a preliminary study, the ratio of changes between the flanks in the photon counts after irradiation was divided by the ratio before irradiation, and the value was expressed as fold activation for evaluation.
Cytotoxicity enhancement using enhanced suicide gene expression by radiation in vitro A well of a 96-well plate was seeded with 2.5Â10 4 cells of a stably transfected cell line and incubated at 37 1C for 24 h. One of the two plates with the same cell line was exposed to X-irradiation at 10 Gy and all the plates were incubated at 37 1C for 12 h. The medium was then replaced by a medium containing 5-FC (Sigma-Aldrich Inc.) at concentrations of 0, 1, 10 or 100 mM, and the plates were incubated again at 37 1C for 24 h. After the incubation period, the medium containing 5-FC was replaced by fresh growth medium without 5-FC and incubated at 37 1C for 24 h. After addition of 10 ml of the WST-1 dye of the Cell Counting kit (Dojindo Laboratories, Kumamoto, Japan) to each well followed by incubation at 37 1C for 2 h, absorbance of the medium was measured at 450 nm as an indicator for viable or surviving cells by using a microplate reader (Model 550; Bio-Rad Laboratories). The absorbance of the medium in a well without cells was also measured as a background, which was subtracted from the measured absorbance of each well. The results were expressed as percentages of the survival cell fraction (SC) calculated using the following formula:
where AS is the absorbance of a sample at 450 nm and AC is absorbance of the control at 450 nm. The control was obtained by using identically cultured cells without 5-FC treatment.
Nucleotide sequence analyses
For confirmation of the constructed promoters, nucleotide sequence analyses were performed by the cycle sequence PCR method by using the Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA, USA), using the primer pairs 5¢-ctttatgtttttggcgtcttcc-3¢ and 5¢-ctagcaaaataggctgtcccc-3¢. Briefly, a DNA sequencing mixture containing 3.2 pmol of each of a pair of primer oligonucleotides, 500 ng of a template plasmid vector DNA and 8 ml of the premix from the kit were subjected to PCR reaction by using the Gene Amp PCR System 9700 (Applied Biosystems). The purified reaction product was subjected to 4% polyacrylamide gel electrophoresis for nucleotide sequencing (ABI PRISM DNA Sequencer 377; PerkinElmer Life and Analytical Sciences, Boston, MA, USA). The DNA nucleotide sequence data of clone 880 and clone 880-8 were submitted in the GenBank database and were assigned the accession numbers HQ418221 and HQ418222, respectively.
Statistical analysis
All values are expressed as means ± s.d.s. Differences were assessed with by Student's unpaired t-test. For comparison of more than two groups, one-way analysis of variance was used. Statistical significance was established at a value of Po0.05.
